Genesys HTA System receives FDA approval for treatment of menorrhagia

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its Genesys HTA™ System for the treatment of menorrhagia.  The Genesys HTA System is a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia.

Menorrhagia is abnormally heavy and prolonged menstrual bleeding.  An estimated 10 million women in the U.S. suffer from this condition.  

The Genesys HTA System represents a significant advance in Boston Scientific's endometrial ablation technology.  It features a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface which offers step-by-step guidance through the procedure.  The System also incorporates several technology upgrades designed to improve operating performance while delivering the same proven clinical therapy of the Company's current HTA Endometrial Ablation System.

"FDA approval of the Genesys HTA System is the latest example of our commitment to developing products in the Women's Health arena that improve patients' lives," said John Pedersen, Senior Vice President and President of Boston Scientific's Urology and Women's Health Division.  "We are pleased we will be able to offer this next-generation system to U.S. patients suffering from menorrhagia."  

The System received CE Mark approval in January.  

"The new Genesys HTA System has streamlined the procedure set-up and provides my patients an effective means to address their menorrhagia," said Christopher Guyer, M.B., B.S., M.R.C.O.G., a gynecologist at Queen Alexandra Hospital, Portsmouth, U.K. 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
UK food policy misses big slice of ultra-processed problem, study finds